BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kalogirou M, Sinakos E. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle? World J Hepatol 2018; 10(11): 790-794 [PMID: 30533179 DOI: 10.4254/wjh.v10.i11.790]
URL: https://www.wjgnet.com/1007-9327/full/v10/i11/790.htm
Number Citing Articles
1
Maria-Styliani Kalogirou, Dimitrios Patoulias, Anna-Bettina Haidich, Evangelos Akriviadis, Emmanouil Sinakos. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trialsClinics and Research in Hepatology and Gastroenterology 2021; 45(3): 101568 doi: 10.1016/j.clinre.2020.10.012
2
Hae Jin Kim. Recent Updates on Glucagon-Like Peptide 1 Receptor AgonistThe Journal of Korean Diabetes 2021; 22(2): 126 doi: 10.4093/jkd.2021.22.2.126
3
Golnaz Ranjbar, Dimitri P. Mikhailidis, Amirhossein Sahebkar. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!Metabolism 2019; 101: 154001 doi: 10.1016/j.metabol.2019.154001
4
Jingya Lyu, Hitomi Imachi, Kensaku Fukunaga, Seisuke Sato, Toshihiro Kobayashi, Tao Dong, Takanobu Saheki, Mari Matsumoto, Hisakazu Iwama, Huanxiang Zhang, Koji Murao. Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytesMolecular Metabolism 2020; 34: 16 doi: 10.1016/j.molmet.2019.12.015
5
Alexander Myint. Improvement of liver function and glycemic control with Combination of DPP-4 inhibitors and GLP-1 agonists in type II diabetes mellitus patients with non-alcoholic steatohepatitisGastroenterology & Hepatology: Open Access 2020; 11(3): 127 doi: 10.15406/ghoa.2020.11.00427
6
Parth Shah, Megan White, Alex Sievert, Alexander Conway, Adam Kneepkens, Gregory Sayuk, Mauricio Lisker‐Melman, Jill Elwing. Semaglutide improves metabolic dysfunction‐associated steatohepatitis: A 10‐year retrospective studyJGH Open 2024; 8(2) doi: 10.1002/jgh3.13037
7
Eleftheria Galatou, Elena Mourelatou, Sophia Hatziantoniou, Ioannis S. Vizirianakis. Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based DrugsAntioxidants 2022; 11(6): 1060 doi: 10.3390/antiox11061060
8
Maja Cigrovski Berkovic, Lucija Virovic-Jukic, Ines Bilic-Curcic, Anna Mrzljak. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and managementWorld Journal of Gastroenterology 2020; 26(21): 2740-2757 doi: 10.3748/wjg.v26.i21.2740
9
Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategiesPharmacological Research 2020; 159: 104984 doi: 10.1016/j.phrs.2020.104984
10
Seol Hwa Seo, Eunhwan Kim, Minguen Yoon, Soung-Hoon Lee, Byung-Hyun Park, Kang-Yell Choi. Metabolic improvement and liver regeneration by inhibiting CXXC5 function for non-alcoholic steatohepatitis treatmentExperimental & Molecular Medicine 2022; 54(9): 1511 doi: 10.1038/s12276-022-00851-8
11
Donna Lee, Joel Zonszein. A Case-Based Guide to Clinical Endocrinology2022; : 369 doi: 10.1007/978-3-030-84367-0_40
12
Ja Young Jeon, Hae Jin Kim. Stroke Revisited: Diabetes in StrokeStroke Revisited 2021; : 167 doi: 10.1007/978-981-16-5123-6_14
13
Chloe Wong, Ming Hui Lee, Clyve Yu Leon Yaow, Yip Han Chin, Xin Lei Goh, Cheng Han Ng, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Chin Meng Khoo. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-AnalysisFrontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.609110
14
E. S. Shcherbakova, T. S. Sall, S. I. Sitkin, T. Ya. Vakhitov, E. V. Demyanova. The role of bacterial metabolites derived from aromatic amino acids in non-alcoholic fatty liver diseaseAlmanac of Clinical Medicine 2020; 48(6): 375 doi: 10.18786/2072-0505-2020-48-066
15
ARKA DE AJAY DUSEJA. Future pharmacotherapy for non-alcoholic steatohepatitisThe National Medical Journal of India 2022; 34: 225 doi: 10.25259/NMJI_103_21
16
Joeri Lambrecht, Leo A. van Grunsven, Frank Tacke. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosisExpert Opinion on Pharmacotherapy 2020; 21(13): 1637 doi: 10.1080/14656566.2020.1774553
17
Ruben Vazquez-Uribe, Karl Alex Hedin, Tine Rask Licht, Max Nieuwdorp, Morten O.A. Sommer. Advanced microbiome therapeutics as a novel modality for oral delivery of peptides to manage metabolic diseasesTrends in Endocrinology & Metabolism 2024;  doi: 10.1016/j.tem.2024.04.021
18
Manoj K. Mahapatra, Muthukumar Karuppasamy, Biswa M. Sahoo. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative ReviewPharmaceutical Research 2022; 39(6): 1233 doi: 10.1007/s11095-022-03302-1
19
Yunzhi Chen, Xuemei Yan, Xiao Xu, Shuhua Yuan, Fen Xu, Hua Liang. PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatideEndocrine 2020; 70(3): 517 doi: 10.1007/s12020-020-02470-7